ylliX - Online Advertising Network
Press Release

AcelRx Pharmaceuticals Announces Publication of Clinical Data on the Use of Sufentanil Sublingual Tablet during Awake Plastic Surgery Procedures

AcelRx Pharmaceuticals Announces Publication of Clinical Data on the Use of Sufentanil Sublingual Tablet during Awake Plastic Surgery Procedures

<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>

HAYWARD, Calif., Feb. 1, 2022 /PRNewswire/ — AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of real-world data in patients undergoing awake plastic surgery showing a rapid recovery time and minimal side effects with the use of sufentanil sublingual tablet (SST) for pain management.

...read full article on PRNewsWire

ylliX - Online Advertising Network